Wave Life Sciences' WVE-004 was developed as a stereopure antisense oligonucleotide targeting the C9orf72 gene mutation linked to ALS and FTD. The termination of the trial due to lack of clinical benefit despite reductions in poly(GP) levels raises significant concerns regarding the asset's viability in the competitive landscape of neurodegenerative disease therapies. The ALS and FTD markets are characterized by high unmet need and limited treatment options, but the failure of WVE-004 may hinder Wave's position and investor confidence. Future strategic considerations may include pivoting towards alternative therapeutic approaches or indications.